Enovis slightly beats Q2 sales estimates, reaffirms  2026 guidance

Enovis

06/08/2026 11:14

Overview
U.S. medical technology firm's Q2 sales rose 3%, slightly beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS and free cash flow

Outlook
Enovis sees 2026 revenue between $2.31 bln and $2.37 bln, 4-6% organic growth
Company expects 2026 adjusted EBITDA of $425-435 mln
Enovis forecasts 2026 adjusted EPS at $3.52-$3.73

Result Drivers
RECONSTRUCTIVE SEGMENT - Sales in Reconstructive grew 8% on a reported basis and 6% organically, reflecting continued execution and new product momentum
COMMERCIAL EXECUTION - Management said improved commercial execution and a more focused organization contributed to results

Company press release: ID:nGNXc84D09

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales 
Slight Beat*
$582.78 mln
$582.54 mln (12 Analysts)
Q2 Adjusted EPS
Beat
$0.90
$0.85 (12 Analysts)
Q2 Gross Margin
 
61.60%
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Enovis Corporation is $40.00, about 32.5% above its August 5 closing price of $30.18

Reuters Recommended Reads
Aug 5 - Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand
Aug 4 - UK's Smith+Nephew cuts 2026 revenue view on weak US knee implant demand
Aug 5 - Orthofix Medical Q2 sales slightly beat estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)